In further subgroup analyses, we assessed associations between 27-HC, 25-HC, and breast cancer prognosis by endocrine therapy use due to a potential interaction between the endogenous ER modulators 27-HC and 25-HC and endocrine therapy. This evidence concerns the gene ESR1 and breast carcinoma.